Clik here to view.
Beovu® shows positive results in two-year Phase III trial
Novartis has announced the first interpretable results from year two (week 100) of the Phase III KESTREL study. KESTREL assessed the safety and efficacy of Beovu® (brolucizumab) 6mg in patients with...
View ArticleClik here to view.
Injectable small molecule inhibitor could improve vision
Positive results from the long-term follow-up of a Phase II study of small molecule inhibitor UBX1325 in patients with diabetic macular edema (DME) have been announced. “UBX1325 achieved visual...
View ArticleClik here to view.
Genentech to reveal new data for ocular biologic
Late-breaking post-hoc data on Vabysmo® (faricimab-svoa), the first bispecific antibody (bsAb) approved for treating the eye, is set to be revealed at the 2023 American Society of Retina Specialists...
View ArticleClik here to view.
Sandoz to file for approval of aflibercept biosimilar
Sandoz has announced positive results from the MYLIGHT Phase III study for its biosimilar aflibercept, for patients living with wet macular degeneration. The confirmatory efficacy and safety study...
View ArticleClik here to view.
Ophthalmology acquisition to advance tri-specific antibody
Merck (known as MSD outside of the US and Canada) plans to acquire Eyebiotech Limited, with the aim to advance development of novel treatments for vision disorders. The deal has a potential value of $3...
View Article